等待開盤 10-31 09:30:00 美东时间
+0.260
+0.42%
 華盛通
華盛通Cytek Biosciences has launched a two-part research initiative in partnership with ISAC to expand access to flow cytometry worldwide. The first phase involves awarding a three-laser Cytek Northern Lights flow cytometer, while the second phase plans to introduce a grant program to fund research projects. These efforts aim to support under-resourced labs and advance global scientific equity, building on previous collaborations like donating equipmen...
10-29 21:00
Insiders have been trading these 5 stocks: (($FITB)), (($HEI)), (($TDG)), (($CY...
10-25 21:01
Cytokinetics, Incorporated will report third quarter 2025 results on November 5, 2025 at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM ET. The event will be webcast and archived on Cytokinetics’ website for six months. The company specializes in developing cardiovascular treatments and advancing potential new medicines like aficamten, omecamtiv mecarbil, ulacamten, and CK-089 for heart conditions and muscular dystrophy.
10-22 20:00
Insiders have been trading these 5 stocks: (($VRSN)), (($HEI)), (($TDG)), (($AC...
10-18 21:01
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
10-18 04:00
Cytek Biosciences has relocated its European headquarters to a new facility in Amsterdam’s Life Sciences District, expanding its presence in the EMEA region. The new site includes offices, warehouse, and a dedicated training center with a functional lab environment for hands-on training. This expansion reflects Cytek’s commitment to delivering advanced cell analysis solutions and enhancing operational efficiency. The move underscores Europe’s imp...
10-15 21:00
今日重点评级关注:Ascendiant Capital:维持PAVmed"买入"评级,目标价从19美元升至20美元;Ascendiant Capital:维持Plus Therapeutics"买入"评级,目标价从20.5美元升至21美元
10-07 15:04
Barclays analyst Gena Wang maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $71 to $82.
10-06 21:00
What's the most attractive Big Pharma stock right now? We asked Seeking Alpha analysts The Value Portfolio and ALLKA Research for their picks. The Value Portfolio: I'd say the most attractive Big Pha...
10-06 05:42
今日重点评级关注:Maxim Group:维持Kazia Therapeutics"买入"评级,目标价从15美元升至20美元;Baird:维持Taysha Gene Therapies"跑赢大市"评级,目标价从7美元升至12美元
10-03 14:32